Vancouver, Canada, Oct. 28, 2025 — Augurex Life Sciences announced FDA Breakthrough Device Designation for its SPINEstat® blood test, the first-in-class diagnostic for early detection of Axial Spondyloarthritis (axSpA), an autoimmune inflammatory condition that affects the spine.

Science Significance

SPINEstat® identifies disease-specific autoantibodies to the 14-3-3η protein, enabling earlier and more accurate diagnosis of axSpA — a condition often misdiagnosed for years. This breakthrough in biomarker science and immunoassay technology may redefine early-stage rheumatologic diagnostics and patient management.

Regulatory Significance

Receiving FDA Breakthrough Device Designation indicates recognition of SPINEstat® as an innovation addressing an unmet medical need. This status allows for prioritized review and closer FDA interaction, potentially accelerating the path to market while maintaining compliance with in-vitro diagnostic regulatory standards.

Business Significance

Advertisement

cGxPJobs Banner

The designation enhances Augurex’s strategic value and investor confidence, positioning it as a global leader in autoimmune diagnostics. The decision supports expansion into the U.S. market and may attract commercial partnerships and licensing opportunities within the precision-medicine sector.

Patients’ Significance

For patients with chronic back pain due to undiagnosed axSpA, the SPINEstat® test offers earlier detection, faster treatment, and better outcomes. Early diagnosis can prevent irreversible joint damage and improve quality of life, marking a major advance in patient-centered care.

Policy Significance

This recognition underscores FDA’s continued support for biomarker-based innovation that can reduce diagnostic delays and healthcare costs. It aligns with international efforts to integrate molecular diagnostics into standard care for autoimmune and inflammatory diseases.

Augurex’s FDA Breakthrough designation for SPINEstat® signals a defining step forward in diagnostic innovation. With its blend of scientific rigor, regulatory achievement, and patient benefit, SPINEstat® positions Augurex at the forefront of translational biomarker science — an advancement highly relevant to the Bio-Pharma ecosystem.

Source: Augurex Life Sciences press release